Tango Therapeutics Stock In The News

TNGX Stock  USD 3.10  0.16  5.44%   
Our overall analysis of Tango Therapeutics' news coverage and content from conventional and social sources shows investors' bearish mood towards Tango Therapeutics. The specific impact of Tango Therapeutics news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Tango Therapeutics' overall financial health and prospects. It also depends on the type and quality of a news publisher.
  
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Tango Therapeutics headlines in addition to utilizing other, more conventional financial analysis modules. Check out Tango Therapeutics Backtesting and Tango Therapeutics Hype Analysis.
For more information on how to buy Tango Stock please use our How to Invest in Tango Therapeutics guide.

Tango Therapeutics Today Top News and Investor Outlook

Yahoo News
Tango Therapeutics Shuts Early-Stage Cancer Study Due To Liver Toxicity
https://finance.yahoo.com/news/tango-therapeutics-shuts-early-stage-185311309.html
 Neutral
Yahoo News
13 Best Short Squeeze Stocks To Buy Now
https://finance.yahoo.com/news/13-best-short-squeeze-stocks-090055208.html
 Bullish
Yahoo News
16 Most Promising Long-Term Stocks According to Analysts
https://finance.yahoo.com/news/16-most-promising-long-term-114551260.html
 Bullish
Yahoo News
12 Most Promising Cancer Stocks According to Analysts
https://finance.yahoo.com/news/12-most-promising-cancer-stocks-195805509.html
 Neutral
Yahoo News
Harvard University Stocks List: Top 12 Picks
https://finance.yahoo.com/news/harvard-university-stocks-list-top-140826502.html
 Bullish
Macroaxis News: globenewswire.com
Tango Therapeutics to Highlight Preclinical Data on PRMT5 Inhibitors at the Society for Neuro-Oncology (SNO) 28th Annual Meeting
https://www.globenewswire.com/news-release/2023/11/13/2778873/0/en/Tango-Therapeutics-to-Highlight-Preclinical-Data-on-PRMT5-Inhibitors-at-the-Society-for-Neuro-Oncology-SNO-28th-Annual-Meeting.html
 Neutral
Macroaxis News: globenewswire.com
Tango Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Highlights
https://www.globenewswire.com/news-release/2023/11/08/2776059/0/en/Tango-Therapeutics-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Business-Highlights.html
 Neutral
Macroaxis News: globenewswire.com
Tango Therapeutics to Present at the Jefferies London Healthcare Conference
https://www.globenewswire.com/news-release/2023/11/07/2774906/0/en/Tango-Therapeutics-to-Present-at-the-Jefferies-London-Healthcare-Conference.html
 Bearish
Macroaxis News: globenewswire.com
Tango Therapeutics to Highlight Preclini...
https://www.globenewswire.com/news-release/2023/09/18/2744640/0/en/Tango-Therapeutics-to-Highlight-Preclinical-Data-on-Precision-Oncology-Pipeline-at-AACR-NCI-EORTC-International-Conference-on-Molecular-Targets-and-Cancer-Therapeutics.html
 Neutral
Macroaxis News: globenewswire.com
Tango Therapeutics Announces FDA Clearan...
https://www.globenewswire.com/news-release/2023/09/06/2738183/0/en/Tango-Therapeutics-Announces-FDA-Clearance-of-Investigational-New-Drug-Application-for-TNG348-a-Novel-USP1-Inhibitor-for-the-Treatment-of-BRCA1-2-mutant-and-Other-HRD-Cancers.html
 Neutral

Tango Therapeutics Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Tango and other traded companies coverage with news coverage. We help investors stay connected with Tango headlines for the 21st of December to make an informed investment decision based on correlating the impacts of news items on Tango Stock performance. Please note that trading solely based on the Tango Therapeutics hype is not for everyone as timely availability and quick action are needed to avoid losses.
Tango Therapeutics' linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help Tango Therapeutics investors visualize upcoming and past events in order to time the market based on Tango Therapeutics noise-free hype analysis.
Tango Therapeutics stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Tango earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Tango Therapeutics that are available to investors today. That information is available publicly through Tango media outlets and privately through word of mouth or via Tango internal channels. However, regardless of the origin, that massive amount of Tango data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Tango Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Tango Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Tango Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Tango Therapeutics alpha.

Tango Largest EPS Surprises

Earnings surprises can significantly impact Tango Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2021-08-06
2021-06-30-0.145-0.16-0.01510 
2024-05-08
2024-03-31-0.31-0.35-0.0412 
2024-03-18
2023-12-31-0.28-0.32-0.0414 
2022-08-10
2022-06-30-0.32-0.280.0412 
2024-11-06
2024-09-30-0.37-0.270.127 
2024-08-07
2024-06-30-0.34-0.240.129 
View All Earnings Estimates

Tango Therapeutics Stock Latest Headlines

Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Tango Therapeutics Stock. The global stock market is bearish. About 65% of major world exchanges and indexes are down. See today's market update for more information.
Google News at Macroaxis
9th of December 2024
Tango Therapeutics, Inc. Receives Consensus Recommendation of Buy from Analysts - MarketBe...
at news.google.com 
businesswire News
3rd of December 2024
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635
at businesswire.com 
Yahoo News
27th of November 2024
Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
at finance.yahoo.com 
news
19th of November 2024
Tango Therapeutics, Inc. Director Purchases 37,800.00 in Stock
at thelincolnianonline.com 
Macroaxis News
14th of November 2024
Acquisition by Rothenberg Mace of 10000 shares of Tango Therapeutics at 3.62 subject to Ru...
at MacroaxisInsider 
news
8th of November 2024
Tango Therapeutics, Inc. Insider Boxer Capital Management, Llc Sells 3,080,000 Shares of S...
at thelincolnianonline.com 
businesswire News
6th of November 2024
Tango Therapeutics Reports Positive TNG462 Clinical Data and Provides Update on PRMT5 Deve...
at businesswire.com 
Google News at Macroaxis
26th of September 2024
Tango Therapeutics, Inc. Receives 15.14 Average Target Price from Analysts - MarketBeat
at news.google.com 

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Tango Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Tango Therapeutics' short interest history, or implied volatility extrapolated from Tango Therapeutics options trading.

Additional Tools for Tango Stock Analysis

When running Tango Therapeutics' price analysis, check to measure Tango Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tango Therapeutics is operating at the current time. Most of Tango Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tango Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tango Therapeutics' price. Additionally, you may evaluate how the addition of Tango Therapeutics to your portfolios can decrease your overall portfolio volatility.